SCHEDULE 13D: 180 Life Sciences CEO Blair Jordan Boosts Beneficial Ownership to 10.5% Through Strategic Voting Agreements and Equity Grant

Blair Jordan, CEO of 180 Life Sciences Corp., has significantly increased his beneficial ownership in the company to 10.5% through new voting agreements and a restricted stock grant, as detailed in a recent Schedule 13D filing.

Summary

• Blair Jordan, Chief Executive Officer of 180 Life Sciences Corp., has filed a Schedule 13D, reporting a beneficial ownership of 403,166 shares of the Issuer's common stock, which represents 10.5% of the total class.
• This beneficial ownership includes 160,000 shares of restricted common stock granted to Mr. Jordan under the Issuer's Third Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan.
• The ownership also encompasses 243,166 shares over which Mr. Jordan has shared voting power due to irrevocable voting proxies obtained from Dr. James Woody (43,166 shares) and Dr. Marlene Krauss (200,000 shares).
• These voting agreements stipulate that Mr. Jordan, or his assigns, will vote the shares as recommended by the Board of Directors, solely for the benefit of the Issuer, without granting him dispositive control or pecuniary interest over these specific shares.
• The 160,000 restricted shares granted to Mr. Jordan are subject to vesting: 80,000 shares on January 1, 2026, and the remaining 80,000 shares on December 31, 2026, contingent upon his continued service to the Issuer.
• In the event of termination by the Issuer without 'cause' or by Jordan Consulting for 'good reason', shares and options scheduled to vest within one year of termination will immediately vest.
• The 10.5% ownership calculation is based on 3,837,780 shares of common stock outstanding, which includes 3,217,780 shares currently outstanding as of February 25, 2025, and an additional 620,000 shares that the Issuer has agreed to issue, including the 160,000 restricted shares for Mr. Jordan.

Sentiment

Score: 7

Explanation: The filing indicates increased alignment between the CEO and the company's long-term interests through equity incentives and enhanced voting control, which is generally positive for corporate governance and stability. However, it's a compliance filing, not an operational update, so the direct impact on immediate financial performance is not detailed.

Positives

• Increased beneficial ownership by the CEO, Blair Jordan, potentially signaling strong alignment with shareholder interests and confidence in the company's future.
• The CEO's compensation package includes significant equity incentives (160,000 restricted shares), aligning his long-term financial interests directly with the company's performance and shareholder value creation.
• Voting agreements with key shareholders (Dr. Woody and Dr. Krauss) provide the Board of Directors, through the CEO, with greater voting control over a significant block of shares (243,166 shares), which can enhance corporate governance stability and facilitate strategic decisions.

Negatives

• The majority of the CEO's reported beneficial ownership (243,166 shares) is derived from voting proxies rather than direct equity ownership, meaning he lacks dispositive control or pecuniary interest over these shares.
• The voting agreements with Dr. Woody and Dr. Krauss are temporary, with specific termination dates (August 21, 2025, and February 5, 2026, respectively), after which the CEO's shared voting power over those shares will cease.

Risks

• The vesting of the 160,000 restricted stock shares granted to Mr. Jordan is contingent upon his continued service to the Issuer, meaning a departure could impact his ultimate beneficial ownership.
• The voting agreements providing shared voting power to Mr. Jordan are time-limited, and their expiration could reduce his overall voting influence within the company.
• The Reporting Person retains the right to change his investment intent and may, from time to time, acquire additional shares or dispose of existing holdings, which could introduce uncertainty regarding future share movements.

Future Outlook

The Reporting Person acquired the securities for investment purposes and may purchase additional securities of the Issuer or dispose of some or all of his current holdings in the future, depending on general market and economic conditions. He may also acquire additional shares under various employee benefit and compensation arrangements. While he currently has no plans for extraordinary corporate transactions, changes in the board or management, capitalization, dividend policy, or corporate structure, he retains the right to modify his plans and formulate proposals that could result in such events, subject to applicable laws and regulations.

Management Comments

• "The Reporting Person acquired the securities for investment purposes."
• "The Reporting Person does not currently have any plans or proposals which relate to or would result in the following described: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure...; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted...; (i) A class of equity securities of the Issuer becoming eligible for termination of registration...; or (j) Any action similar to any of those enumerated above."
• "The Reporting Person retains the right to change his investment intent, and may, from time to time, acquire additional shares of Common Stock or other securities of the Company, or sell or otherwise dispose of (or enter into a plan or arrangements to sell or otherwise dispose of), all or part of the shares of Common Stock or other securities of the Company, if any, beneficially owned by him, in any manner permitted by law."
• "However, the Reporting Person, in his capacity as a member of the Board and Chief Executive Officer may, from time to time, become aware of, initiate, and/or be involved in discussions that relate to the transactions described in this Item 4 and thus retains his right to modify his plans with respect to the transactions described in this Item 4 to acquire or dispose of securities of the Company and to formulate plans and proposals that could result in the occurrence of any such events, subject to applicable laws and regulations."

Industry Context

This filing is specific to a change in beneficial ownership for 180 Life Sciences Corp.'s CEO and does not provide information to analyze broader industry trends or competitors.

Corporate Governance

Related Party Transactions

• Executive Consulting Agreement entered into with Blair Jordan Strategy and Finance Consulting Inc., an entity owned by Mr. Jordan.
• Grant of 160,000 restricted common stock shares to Mr. Blair Jordan, the Chief Executive Officer and director of the Issuer.

Stakeholder Impact

• Shareholders: The increased beneficial ownership and voting control by the CEO, coupled with equity-based compensation, can be viewed positively as it aligns management's interests with long-term shareholder value creation and may enhance corporate governance stability.
• Employees: The document primarily focuses on executive compensation and governance, with no direct impact on general employees mentioned.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is mentioned in this filing.

Next Steps

• Vesting of 80,000 restricted shares on January 1, 2026, subject to Mr. Jordan's continued service.
• Vesting of 80,000 restricted shares on December 31, 2026, subject to Mr. Jordan's continued service.
• Termination of the Voting Agreement with Dr. Marlene Krauss by August 21, 2025.
• Termination of the Voting Agreement with Dr. James Woody by February 5, 2026.
• Potential future purchases or dispositions of securities by the Reporting Person, depending on market conditions and investment intent.

Key Dates

Recommendation

Keywords

180 Life Sciences Corp., Blair Jordan, Schedule 13D, Beneficial Ownership, Voting Agreement, Restricted Stock, CEO, Corporate Governance, Equity Compensation, SEC Filing